Cellectis Sa Stock Today
| CLLS Stock | USD 2.13 0.01 0.47% |
Performance0 of 100
| Odds Of DistressOver 54
|
Cellectis is selling for under 2.13 as of the 30th of November 2024; that is 0.47% down since the beginning of the trading day. The stock's lowest day price was 2.09. Cellectis has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Cellectis SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of February 2007 | Category Healthcare | Classification Health Care |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. The company has 100.09 M outstanding shares of which 140.46 K shares are currently shorted by private and institutional investors with about 1.68 trading days to cover. More on Cellectis SA
Moving together with Cellectis Stock
Moving against Cellectis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cellectis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Andre Choulika | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCellectis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cellectis' financial leverage. It provides some insight into what part of Cellectis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellectis SA (CLLS) is traded on NASDAQ Exchange in USA. It is located in 8, rue de la Croix Jarry, Paris, France, 75013 and employs 216 people. Cellectis is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 213.2 M. Cellectis SA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 100.09 M outstanding shares of which 140.46 K shares are currently shorted by private and institutional investors with about 1.68 trading days to cover.
Cellectis SA currently holds about 153.13 M in cash with (24.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cellectis Probability Of Bankruptcy
Ownership AllocationCellectis holds a total of 100.09 Million outstanding shares. Cellectis SA shows 3.86 percent of its outstanding shares held by insiders and 14.76 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cellectis Ownership Details
Cellectis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| First Affirmative Financial Network | 2024-09-30 | 21.1 K | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 16.7 K | |
| Baird Financial Group, Inc. | 2024-09-30 | 15.1 K | |
| Xtx Topco Ltd | 2024-09-30 | 13.1 K | |
| Wells Fargo & Co | 2024-06-30 | 12.8 K | |
| Geode Capital Management, Llc | 2024-09-30 | 10.8 K | |
| Harbour Investments, Inc. | 2024-09-30 | 6.1 K | |
| Rhumbline Advisers | 2024-06-30 | 3.9 K | |
| Blackrock Inc | 2024-06-30 | 2.8 K | |
| Long Focus Capital Management, Llc | 2024-09-30 | 4.6 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 1.8 M |
Cellectis Historical Income Statement
Cellectis Stock Against Markets
Cellectis Corporate Management
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Kyung NamWortman | Executive Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.